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The early detection of relapse following primary surgery for non-small cell lung cancer and the characterization of 
emerging subclones seeding metastatic sites might offer new therapeutic approaches to limit tumor recurrence. The 
potential to non-invasively track tumor evolutionary dynamics in ctDNA of early-stage lung cancer is not established. 
Here we conduct a tumour-specific phylogenetic approach to ctDNA profiling in the first 100 TRACERx (TRAcking 
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Lung cancer is the leading cause of cancer death1,2. Metastatic non-
small cell lung cancer (NSCLC) cannot be cured with systemic 
chemotherapy, yet clinical studies have shown a 5% benefit of post-
operative (adjuvant) chemotherapy on overall survival3. This modest 
survival benefit may reflect a vulnerability of low volume disease within 
the context of reduced intra-tumor heterogeneity4. Circulating tumor 
DNA (ctDNA) detection in plasma following resection of breast5,6 
and colorectal7 tumors has been shown to identify patients destined to 
relapse post-operatively in advance of established clinical parameters. 
Identifying, monitoring and genomically characterizing residual 
disease following primary lung cancer surgery may improve outcomes 
in the adjuvant setting. This would create a therapeutic setting where 
only patients destined to recur would receive treatment and where 
intervention could be directed to the evolving tumor subclone that is 
seeding metastatic recurrence.
Here, we report a bespoke multiplex-PCR NGS approach to ctDNA 
profiling within the context of the prospective tumor evolutionary 
NSCLC TRACERx study. We address determinants of ctDNA detection 
in early-stage NSCLC and investigate the ability of ctDNA to identify 
and genomically characterize post-operative NSCLC relapse within a 
tumor phylogenetic framework.
Phylogenetic ctDNA profiling
The TRACERx study monitors the clonal evolution of NSCLC from 
diagnosis through to death8,9. Using multi-region exome sequencing 
(M-Seq) derived tumor phylogenetic trees developed through prospec-
tive analysis of a 100 patient TRACERx cohort, we conducted a phy-
logenetic approach to ctDNA profiling in early-stage NSCLC (Fig. 1). 
Bespoke multiplex-PCR assay-panels were synthesised for each patient, 
targeting clonal and subclonal single nucleotide variants (SNVs) 
selected to track phylogenetic tumor branches in plasma (Fig. 1). 
SNV detection in plasma was established through a calling algorithm 
employing negative control samples (see Methods). Analytical valida-
tion of the multiplex-PCR NGS platform demonstrated a sensitivity 
of above 99% for the detection of SNVs at frequencies above 0.1% and 
the specificity of detecting a single SNV was 99.6% (Extended Data 
Fig. 1a). At least two SNVs were detected in ctDNA from early-stage 
NSCLCs analyzed in our published discovery cohort data10, demon-
strating biological sensitivity of a two SNV threshold for ctDNA detec-
tion. Therefore, we prospectively selected a threshold of two detected 
SNVs for calling a sample ctDNA positive for validation within this 
study; to minimize type I error when testing up to 30 tumour-specific 
SNVs per time-point in a single patient (see Extended Data Fig. 1b for 
justification).
Determinants of ctDNA detection in NSCLC
We sought to identify clinicopathological determinants of ctDNA 
detection in early-stage NSCLC by profiling pre-operative plasma sam-
ples in 100 TRACERx patients. Samples from four patients could not 
be analyzed (see cohort design Extended Data Fig. 2a, patient chara-
cteristics Extended Table 1a-c, Supplementary Table 1). Individual 
assay-panels were designed to target a median of 18 SNVs (range 10 
to 22) comprising a median of 11 clonal SNVs (range 2 to 20) and a 
median of 6 subclonal SNVs (range 0 to 16) per patient (Extended 
Data Fig. 2b,e).
At least two SNVs were detected in ctDNA pre-operatively in 
46 of 96 (48%) early-stage NSCLCs and a single SNV was detected 
in 12 additional cases (Fig. 2a). Centrally reviewed pathological data 
revealed that ctDNA detection was associated with histological sub-
type: 97% (30/31) of lung squamous cell carcinomas (LUSCs) and 71% 
(5 of 7) of other NSCLC subtypes were ctDNA positive, compared with 
19% (11/58) of lung adenocarcinomas (LUADs) (Fig. 2a). 94% (16 of 
17) of stage I LUSCs were detected compared with 13% (5 of 39) of 
stage I LUADs (Extended Data Fig. 3a). Passive release of ctDNA into 
the circulation may be associated with necrosis11. As expected LUSCs 
were significantly more necrotic than LUADs12 and ctDNA positive 
LUADs formed a sub-group of more necrotic tumors compared with 
ctDNA negative LUADs (Extended Data Fig. 3b). Necrosis, lymph 
node involvement, lymphovascular invasion, pathological tumor 
size, Ki67 labelling indices, non-adenocarcinoma histology and total 
cell-free DNA input predicted ctDNA detection in univariable analyses 
(Extended Data Fig. 3c). Multivariable analysis revealed non- 
adenocarcinoma histology, the presence of lympho-vascular invasion 
and high Ki67 proliferation index as independent predictors of ctDNA 
detection (Extended Data Fig. 3c). Since FDG-avidity on positron emi-
ssion tomography (PET) scans correlates with proliferative indices in 
early-stage NSCLC13,14, we investigated tumor PET FDG-avidity and 
ctDNA detection. PET FDG-avidity predicted ctDNA detection (area 
under curve = 0.84, P < 0.001, n = 92) (Extended Data Fig. 3d). Within 
LUADs, driver events in KRAS, EGFR or TP53 were not associated with 
ctDNA detection (Extended Data Fig. 3e).
We analyzed the distribution of clonal and subclonal SNVs in 
ctDNA positive patients. Clonal SNVs were detected in all 46 ctDNA 
positive patients and a median of 94% (range 11% to 100%) of clonal 
SNVs targeted by assay-panels were detected in the ctDNA of these 
patients. 40 of 46 ctDNA positive patients had subclonal SNVs tar-
geted by assay-panels and subclonal SNVs were detected in 27 (68%) 
of these patients. A median of 27% (range 0% to 91%) of subclonal 
SNVs within individual assay-panels were detected in ctDNA positive 
patients (Fig. 2b). The mean plasma variant allele frequency (VAF) 
of clonal SNVs was higher than that of subclonal SNVs (Extended 
Data Fig. 4a, within patient comparison, Wilcoxon signed-rank test, 
P < 0.001, n = 27, Supplementary Table 2) supporting the use of clonal 
alterations as a more sensitive method of ctDNA detection than sub-
clonal alterations10,15.
In ctDNA positive patients, pathologic tumor size correlated with 
mean clonal plasma VAF (Spearman’s Rho = 0.405, P = 0.005, n = 46, 
Extended Data Fig. 4b). CT scan volumetric analyses were available in 
38 of 46 ctDNA positive patients (see Extended Data Fig. 4c). Tumor 
volume correlated with mean clonal plasma VAF (Fig. 3a, Spearman’s 
Rho = 0.61, P < 0.001, n = 38). A linear relationship between log- 
transformed volume and log- transformed mean clonal VAF values 
was observed (Fig. 3a). The line of best fit applied to the data was 
consistent with the line fitted to NSCLC volumetric data and ctDNA 
plasma VAFs reported in previously published work16 (Extended Data 
Fig. 4d). Linear modelling based on the TRACERx data predicted 
that a primary tumor burden of 10 cm3 would result in a mean clonal 
plasma VAF of 0.1% (95% C.I. 0.05 to 0.17%) (Fig. 3b). Tumor purity 
was multiplied by tumor volume to control for stromal contamination 
to determine cancer cell volume corresponding to clonal plasma VAF 
(Extended Data Fig. 4e). On the assumption that 1 cm3 of pure tumor 
contains 9.4 x 107 cells17, a plasma VAF of 0.1% would correspond 
to a primary NSCLC malignant burden of 326 million cells (Fig. 3b, 
Extended Data Fig. 4f).
non-small cell lung Cancer Evolution through therapy (Rx)) study participants, including one patient co-recruited to 
the PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We identify independent 
predictors of ctDNA release and perform tumor volume limit of detection analyses. Through blinded profiling of 
post-operative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients destined to 
experience recurrence of their lung cancer. Finally, we show that phylogenetic ctDNA profiling tracks the subclonal 
nature of lung cancer relapse and metastases, providing a new approach for ctDNA driven therapeutic studies 
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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To investigate predictors of subclone detection, detected subclonal 
SNVs were mapped back to M-seq derived tumor phylogenetic trees. 
35 of 57 (61%) shared subclones (identified in more than one tumor 
region through M-Seq analysis) were identified in ctDNA, compared 
with 26 of 80 (33%) private subclones (detected in a single tumor region 
only) (Extended Data Fig 4g). This suggested subclone volume influ-
ences subclonal ctDNA detection. Subclone volume was estimated 
based on mean regional subclone cancer cell fraction and cancer cell 
volume. Detected subclonal SNVs mapped to subclones with higher 
estimated volumes than subclones containing undetected SNVs 
(Fig. 3c) and subclone volume correlated with subclonal SNV plasma 
VAF (Fig. 3d).
Detecting and characterizing NSCLC relapse
The longitudinal phase of the study aimed to determine if ctDNA profil-
ing with patient-specific assay panels could detect and characterize the 
branched subclone(s) seeding NSCLC relapse. Pre- and post-surgical 
plasma ctDNA profiling was performed blinded to relapse status in a 
sub-group of 24 patients (cohort characteristics, Extended Table 1d-e). 
This included relapse free patients who had been followed-up for a 
median of 775 days (range 688 to 945 days, n = 10) and confirmed 
NSCLC relapse cases (n = 14) (cohort design, Extended Data Fig. 2c). 
Additional PCR assays were added to panels in this phase of the study to 
attempt to improve ctDNA detection in LUADs, a median of 18.5 SNVs 
(range 12 to 20) were targeted by LUSC assay-panels and a median of 28 
SNVs (range 25 to 30) were targeted by LUAD assay-panels (Extended 
Data Fig. 2d-e).
Patients were followed up with three to six monthly clinical assess-
ment and chest radiographs. At least 2 SNVs were detected in 13 
of 14 (93%) patients with confirmed NSCLC relapse prior to, or at, 
clinical relapse (Fig. 4a-g, Extended Data Fig. 5). At least two SNVs 
were detected in 1 of 10 (10%) patients (CRUK0013) with no clinical 
evidence of NSCLC relapse (Fig. 4h, Extended Data Fig. 6). Excluding 
a single case where no post-operative plasma was taken prior to clinical 
relapse (CRUK0041), the median interval between ctDNA detection 
and NSCLC relapse confirmed on clinically indicated CT imaging 
(lead-time) was 70 days (range 10 to 346 days). Four of 13 relapse 
cases exhibited lead-times of more than six months (Fig. 4a-d). In two 
cases ctDNA detection preceded CT imaging inconclusive for NSCLC 
relapse by 157 days (CRUK0004, Fig. 4b) and 163 days (CRUK0045, 
Fig. 4d). ctDNA profiling reflected adjuvant chemotherapy resistance 
- CRUK0080, CRUK0004 and CRUK0062 had detectable ctDNA in 
plasma within 30 days of surgery. The number of detectable SNVs 
increased in all three cases despite adjuvant chemotherapy, with disease 
recurring within 1 year of surgery (Fig. 4a-c). In contrast, CRUK0013 
had 20 SNVs detectable in ctDNA 72 hours after surgery and 13 SNVs 
detectable prior to adjuvant chemotherapy; 51 days following comple-
tion of adjuvant treatment and at post-operative days 457 and 667 no 
SNVs were detectable and the patient remains relapse free 688 days 
post-surgery (Fig. 4h). ctDNA profiling detected intracerebral relapse; 
CRUK0029 had a PET scan performed 50 days prior to surgery demon-
strating normal cerebral appearances. ctDNA remained detectable 
following surgery, 54 days post-operatively the patient was diagnosed 
with intracerebral metastasis, no extracranial disease was evident on 
CT imaging (Fig. 4e).
In cases where subclonal SNVs were detected in ctDNA post- 
operatively we predicted subclonal clusters involved in the relapse 
process by mapping SNVs detected in plasma back to primary M-Seq 
data (Fig. 4, Extended Data Fig. 5b-c). Subclonal SNVs displaying 
plasma VAFs similar to clonal SNVs from clusters confined to a single 
phylogenetic branch, were detected post-operatively in the ctDNA of 
four patients who suffered NSCLC relapse (CRUK0004, CRUK0063, 
CRUK0065 and CRUK0044) (Fig. 4b,f-g, Extended Data Fig 5b). This 
suggested a relapse process dominated by one subclone represented 
in our assay-panel. The subclone implicated by ctDNA as driving 
the relapse in the case of CRUK0004 contained an ERRB2 (HER2) 
amplification event (> 15 copies, triploid background), that may be tar-
getable in NSCLC18 (Fig. 4b). Relapses involving subclones from more 
than one phylogenetic branch were evident in patients CRUK0080, 
CRUK0062 (Fig. 4a,c) and CRUK0041 (Extended Data Fig 5c).
Validation of phylogenetic characterization
To validate subclonal ctDNA analyses, data acquired from sequencing 
metastatic tissue at recurrence was integrated with M-seq primary 
tumor data (for biopsy details, Supplementary Table 3). Patient 
CRUK0063 suffered para-vertebral relapse of their NSCLC. Post-
operative ctDNA analysis revealed the detection of the same subclonal 
SNV (OR5D18) on four consecutive occasions over a 231-day period 
(Extended Data Fig. 7a). The OR5D18 SNV traced back to a subclonal 
cluster private to primary tumor region three (Fig. 5a). CT-guided 
biopsy tissue was acquired from the para-vertebral metastasis at 
post-operative day 467. Exome sequencing of relapse tissue revealed 
the subclonal cluster containing the OR5D18 SNV gave rise to the meta-
static subclone (Fig. 5a), this supported ctDNA phylogenetic charac-
terization of relapse. The para-vertebral biopsy contained 88 SNVs not 
called as present in the primary tumor including an ARID1A stop-gain 
driver SNV. Re-examination of primary tumor region M-Seq data with 
a lower SNV calling threshold revealed that 16 of 88 SNVs, including 
ARID1A, were detectable in primary tumor region three, compared 
to a maximum of 2 of 88 in other tumor regions (Extended Data 
Fig. 7b). These data suggest that ctDNA profiling can resolve the 
primary tumor region from which a low frequency metastatic subclone 
derives. CRUK0035 developed two liver and one adrenal metastases 
(Fig. 5b). Sequencing of the metastatic liver deposit revealed that only 
109 of 149 SNVs classed as clonal in the primary tumor were detectable 
in the metastasis. This was suggestive of an ancestral branching event 
not resolved through primary M-seq analysis (Fig. 5b). Post-operative 
ctDNA profiling identified clonal SNVs present in the liver metastasis 
biopsy but also revealed SNVs representing a subclone from the 
primary tumor (Extended Data Fig 7c). This subclone was not present 
in the metastatic liver deposit (Fig. 5b). These data may reflect ctDNA 
identified from the non-biopsied metastases suggesting multiple 
metastatic events. CRUK0044 suffered a vertebral and right hilar 
relapse. Post-operatively the same subclonal SNV (OR10K1), was 
detected in ctDNA on two occasions 85 days apart (Extended Data 
Fig. 7d). This SNV was represented in a single subclone detected 
through sequencing hilar lymph-node metastatic tissue, supporting 
ctDNA findings (Fig. 5c). CRUK0041 suffered an intracerebral, hilar 
and subcarinal lymph node relapse. Four subclonal SNVs representing 
both branches of the tumor phylogenetic tree were detectable in ctDNA 
at relapse. Consistent with these data, sequencing of subcarinal met-
astatic tissue revealed the presence of subclonal SNVs mapping to 
both phylogenetic branches (Fig. 5d, Extended Data Fig. 7e). Patient 
CRUK0013 had detectable ctDNA 3 and 38 days post-operatively. 
Following adjuvant chemoradiotherapy for lymph-node metastases 
identified in the pathological specimen, ctDNA levels became unde-
tectable (Fig. 4h). Two involved lymph-nodes were sampled for exome 
analysis together with M-seq of the primary tumor. Four subclonal 
SNVs detected in ctDNA post-operatively mapped to an ancestral sub-
clone (describing a subclone that existed during the tumor’s evolution) 
(Extended Data Fig. 7f). This ancestral subclone contained a KRAS 
amplification (> 15 copies, triploid background) and was identified as 
present in primary tumor and sampled lymph-nodes by M-Seq (Fig. 5e). 
These data provide phylogenetic characterization of post-operative 
residual disease that responded to adjuvant chemoradiotherapy (Fig. 4h).
ctDNA profiling in the metastatic setting
Patient CRUK0063 underwent examination through the PEACE 
post-mortem study 24 hours following death. M-Seq data from the 
six post-mortem tumor regions (para-aortic, para-vertebral and lung 
metastases, day 857), the para-vertebral relapse biopsy (day 467) and five 
primary tumor regions (day 0) were combined to infer the phylogenetic 
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
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structure of this patient’s NSCLC (Fig. 6a). All seven metastatic tumor 
regions arose from a single ancestral subclone represented by phy-
logenetic cluster 8. Six metastatic regions shared a later phylogenetic 
origin, cluster 12 (Fig. 6b). The single tumor region not containing 
phylogenetic cluster 12 was sampled from the para-aortic metastasis at 
autopsy and contained a private subclone represented by phylogenetic 
cluster 9 (Fig. 6b).
We designed a bespoke ctDNA assay-panel to retrospectively track 
metastatic subclonal burden. 20 clonal SNVs and a median of 8 sub-
clonal SNVs (range 4 to 15) in each of 9 metastatic subclonal clusters 
were targeted by the assay-panel (Extended Data Fig. 8). Since 103 
variants per time-point were profiled, SNV detection thresholds were 
increased to maintain platform specificity (see Methods). This resulted 
in a predicted false positive rate (FPR) of 0.0011 translating to a 10.7% 
risk of a single false-positive SNV at each time point and a 0.5% risk 
of 2 false-positive SNVs at each time point when testing 103 SNVs.
Two clonal SNVs were detected by the 103 SNV assay-panel at day 
151 post-surgery (Fig. 6c, Extended Data Fig. 8), 189 days prior to 
the time point ctDNA was detected using the 19 SNV assay-panel in 
Fig. 4f. At day 242 a single subclonal SNV was detected from phylo-
genetic cluster 8 (Fig. 6c, Extended Data Fig. 8), within the context of a 
10.7% false-positive risk a single SNV call could represent type I error. 
At day 466, following clinical-relapse at the thoracic para-vertebral site, 
18 of 20 SNVs mapping to phylogenetic clusters (8,11 and 12) were 
detected in ctDNA, these subclonal clusters were shared between six 
of seven metastatic sites (Fig. 6b-c, Extended Data Fig. 8). Single SNVs 
from two private subclones (phylogenetic cluster 5 and 9) were also 
detectable in ctDNA at day 466 (Fig. 6c, Extended Data Fig. 8). These 
subclones were not identified in the CT guided para-vertebral biopsy 
taken at day 467 (Fig. 6b). The mean plasma VAF of the SNVs detected 
in phylogenetic clusters 11, 8, 12, 9 and 5 mirrored their proximity to 
the clonal cluster (light blue) in the M-Seq derived phylogenetic tree 
(Fig. 6a,c). This suggested a tiered burden of subclonal disease con-
cordant with M-seq phylogenetic inferences. Mean clonal VAF fell in 
response to palliative radiotherapy and chemotherapy, but at day 767 
increased (Fig. 6c). Single SNVs mapping to phylogenetic clusters 5 and 
9 and two SNVs mapping to phylogenetic cluster 2 were now detect-
able in ctDNA 90 days before death (Fig. 6a-c, Extended Data Fig 8). 
These three phylogenetic clusters represented subclones private to the 
para-aortic metastases (Fig. 6. a-b). Consistent with these data signifi-
cant para-aortic progression was observed at post-mortem compared 
with most recent CT imaging performed 112 days before death - which 
showed no evidence of para-aortic disease.
Discussion
In summary, we find predictors of ctDNA detection in early-stage 
NSCLC characterized by non-adenocarcinoma histology, necrosis, 
increased proliferative indices and lymphovascular invasion. Triple 
negative breast cancers display necrosis19, high proliferative indices20,21 
and are associated with increased ctDNA levels compared with other 
breast cancer subtypes6 suggesting extension of these observations 
beyond NSCLC.
Tumor volume correlated with plasma ctDNA VAF (Fig. 3a.). 
A primary NSCLC tumor volume of 10 cm3 predicted a ctDNA plasma 
VAF of 0.1%; the VAF conferring optimum sensitivity for most ctDNA 
platforms. Low-dose CT lung screening can identify lung nodules with 
diameters from 4 mm22. Assuming a spherical nodule this would trans-
late to a tumor volume of 0.034 cm3. Based on the relationship between 
tumor volume and ctDNA plasma VAF observed in this study a tumor 
volume of 0.034 cm3 would equate to a plasma VAF of 1.4 x 10-4% (95% 
CI, 6.4 x 10-6 to 0.0031%), at the extreme of detection limits of current 
ctDNA platforms23. Sensitivity of clonal SNV ctDNA directed early 
NSCLC screening may therefore be constrained by tumor size using 
current technologies.
A limitation to targeted ctDNA profiling is cost, estimated at 
$1750 per patient for sequencing a single tumor region, synthesis of 
a patient-specific assay-panel and profiling of five plasma samples. 
Adjuvant platinum-based chemotherapy in NSCLC improves cure rates 
following surgery in only 5% of patients and 20% patients receiving 
chemotherapy experience acute toxicities3. There is a need to increase 
adjuvant therapy efficacy and better target its use. Bespoke ctDNA 
profiling can characterize the subclonal dynamics of relapsing NSCLC 
and identify adjuvant chemotherapy resistance. These findings indicate 
that drug development guided by ctDNA platforms to identify residual 
disease, define adjuvant treatment response and target emerging sub-
clones prior to clinical recurrence in NSCLC, with appropriate CLIA 
validation, are now feasible.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Figure 1 | Phylogenetic ctDNA tracking. Overview of the study 
methodology. Multi-region sequencing of NSCLC was performed as 
part of the TRACERx study. PCR assay-panels were designed based on 
phylogenetic analysis, targeting clonal and subclonal single nucleotide 
variants to facilitate non-invasive tracking of the patient-specific tumor 
phylogeny. Assay-panels were combined into multiplex assay-pools 
containing primers from up to 10 patients. Cell-free DNA was extracted 
from pre- and post-operative plasma samples and multiplex-PCR 
performed, followed by sequencing of amplicons. Findings were integrated 
with M-Seq exome data to track tumor evolution.
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Figure 2 | Clinicopathological predictors of ctDNA detection.  
a) Heatmap showing clinicopathological and ctDNA detection data, 
continuous variables quartiled. Raw data and patient IDs in attached 
worksheet. b) Detection of clonal and subclonal single nucleotide variants 
within 46 patients with two or more single nucleotide variants detected in 
plasma. Histology indicated in panels as LUSC, LUAD and Other.
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Figure 3 | Tumor volume predicts plasma variant allele frequency. a) 
Tumor volume (cm3) measured by CT volumetric analysis correlates with 
mean clonal plasma VAF, n = 38, grey vertical lines represent range of 
clonal VAF, red shading indicates 95% confidence intervals. b) Predicted 
mean clonal VAF at hypothetical volumes ranging from 1 to 100 cm3 
based on model in panel a, predicted cancer cell number based on model 
in extended data 4e. c) Estimated effective subclone size, defined as mean 
CCF of subclone multiplied by tumor volume and purity, influences 
subclonal SNV detection. For negative calls, median effective subclone 
size was 1.70 cm3, range = 0.21-24.11, n = 163, for positive calls, median 
effective subclone size = 4.06 cm3, range = 0.31 – 49.20, n = 109. Wilcoxon 
rank sum test, P < 0.001, data from 34 patients (passed volumetric filters 
with subclonal SNVs represented in assay-panel). d) Estimated effective 
subclone size correlates with subclonal plasma VAF, n = 109 subclonal 
SNVs, data from 34 patients (passed volumetric filters with detected 
subclonal SNVs in plasma).
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Figure 4 | Post-operative ctDNA detection predicts and characterizes 
NSCLC relapse. a-h) Longitudinal cell-free DNA profiling. Circulating 
tumor DNA (ctDNA) detection in plasma was defined as the detection 
of two tumor-specific SNVs. Detected clonal (circles, light blue) and 
subclonal (triangles, colors indicates different subclones) SNVs from 
each patient-specific assay-panel are plotted on graphs colored by 
M-Seq derived tumor phylogenetic nodes. Mean clonal (blue) and mean 
subclonal (red) plasma VAF are indicated on graphs as connected lines. 
Pre-operative and relapse M-Seq derived phylogenetic trees represented by 
ctDNA are illustrated above each graph.
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Figure 5 | Phylogenetic trees incorporating relapse tissue sequencing 
data. Phylogenetic trees based on mutations found in primary and 
metastatic tissue (a-d), or primary tumor and lymph node biopsies (e). 
Colored nodes in phylogenetic trees indicate cancer clones harboring 
mutations assayed for in ctDNA, grey indicates a clone not assayed. Branch 
length is proportional to number of mutations unless crossed. Dashed red 
lines show branches leading to metastatic relapse. Colored bars below show 
the number of assays per sample detected preoperatively and at relapse 
(a-d) or in the absence of relapse, post-surgery (e). Thin colored bar shows 
number of assays in total. Colors match clones on the phylogenetic trees.
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Relapse site
Figure 6 | ctDNA tracking of lethal cancer subclones in CRUK0063. 
Phylogenetic analysis of one relapse biopsy (day 467) and five metastatic 
biopsies (post mortem) a) To-scale phylogenetic tree of CRUK0063 
including M-seq based on metastatic and primary tumor regions. Branch 
length is proportional to number of mutations in each subclone. b) 
Phylogenetic trees matching metastatic lesions, colored nodes represent 
mutation clusters found at each site and assayed for in ctDNA. Open 
circles represent mutation clusters not detected in ctDNA. c) Tracking 
plot showing mean VAF of identified mutation clusters in ctDNA. Size of 
dots indicates number of assays detected. Colors correspond to mutation 
clusters and match panels a) and b).
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METHODS
Patients and samples. The cohort of 100 patients evaluated within this study com-
prises the first 100 patients prospectively analyzed by the lung TRACERx study 
(Clinicaltrials.gov no: NCT01888601, approved by an independent Research Ethics 
Committee, 13/LO/1546) and mirrors the prospective 100 patient cohort by Jamal-
Hanjani M et al9.
Multi-region tumor sampling was performed as described9. Relapse tissue 
samples, excess to diagnostic requirements, were acquired via clinical proce-
dures detailed in Supplementary Table 3. For patient CRUK0063 post mortem 
examination was performed through the PEACE study 24 hours following death 
(Clinicaltrials.gov no: NCT03004755, approved by an independent Research Ethics 
Committee, 13/LO/0972). Informed consent was obtained from all subjects for 
procedures conducted in these studies.
Tissue microarray creation and Ki67 immunohistochemistry. Tissue microar-
rays (TMAs) were created of 100 NSCLC cases for Ki67+ immunohistochemistry. 
Representative primary tumor areas were defined by examination of H&E stained 
sections from TRACERx cases. Two 2 mm cores were selected from different 
regions within each specimen and re-embedded in recipient blocks. This resulted 
in a TMA of 200 cores with four normal lung cores as negative control. 2-5 µ m sec-
tions from tissue-microarrays containing tumor were cut. Immunohistochemistry 
with anti-Ki67 monoclonal antibody (Dilution 1:100; clone MIB-1; DAKO Agilent 
Technologies LDA, UK Limited, Stockport, Cheshire SK8 3GR, UK) was per-
formed using BenchMark Ultra (Ventana/Roche). The percentage of Ki67 pos-
itive cells were averaged across two tumor sections for each case. Detection was 
performed using the peroxidase-based detection reagent conjugate (OptiView DAB 
IHC Detection Kit; Ventana Medical Systems, Inc).
Central histopathological review. Digital images of diagnostic tumor sections 
from all cases were reviewed in detail centrally by at least one pathologist, and in 
cases of uncertainty, by two. Histological subtype, percentage of necrosis and the 
presence of lymphovascular invasion were all evaluated on digital images from 
scanned diagnostic slides blinded to the ctDNA detection status of the patient 
in question.
Central radiology review & volume estimation. 92 of 96 anonymized diagnos-
tic PET-CT were reviewed by a Nuclear Medicine Physician, blinded to the ini-
tial PET-CT reports. Scan images were not available in three cases (CRUK0025, 
CRUK0039 and CRUK0023) and in one case a pre-operative PET-CT was not per-
formed (CRUK0082). CT and PET images were matched and fused into transax-
ial, coronal and sagittal images and reviewed on a dedicated PET/CT software 
visualizer (AW 4.1/4.2 GE medical systems). The semi-quantitative parameter 
Standardized Uptake Value (SUV) max for the primary tumor mass was calculated 
and recorded along with SUVmax of mediastinal background uptake. Tumor-to-
background ratio (TBR) was calculated based on SUVmax of the tumor divided 
by mediastinal background uptake24,25. Tumor volume was determined based on 
tumor CT scans. CT slices of the primary tumor were measured with 3D Slicer 
applying the “lung algorithm window” settings, tumor contours were segmented 
on each axial CT slice. These steps were performed by an experienced resident 
(W.L.B.), and all contours were confirmed and edited where necessary, by a radiolo-
gist with 14 years of experience in cancer imaging (F.M.F.). Effective tumor volume 
was defined as tumor volume multiplied with the mean purity of the tumor based 
on M-seq, purity estimates derived from ASC T analysis as described9. Effective 
subclone size was defined as mean cancer cell fraction (CCF) across the regions of 
the mutation cluster multiplied by tumor volume and mean tumor purity.
Tissue exome sequencing and processing. Whole exome sequencing was per-
formed on DNA purified from tumor tissue and normal blood as described9, with 
the exception of CRUK0063_BR_T1-R1. This capture was performed according to 
the manufacturer’s 200 ng DNA protocol (Agilent). Annotated SNV calls from pri-
mary tumors are available in Jamal-Hanjani et al. 20179. For this study, metastatic 
tissue biopsies from each of four patients (CRUK0035, CRUK0041, CRUK0044, 
CRUK0063) and six metastatic samples acquired at post mortem examination of 
CRUK0063 were obtained. Genomic DNA was purified from all tissue samples, and 
processed through the TRACERx bioinformatics pipeline as described9. Annotated 
SNV calls are available in Supplementary Table 4.
cfDNA extraction & quantification. Blood samples were collected in K2-EDTA 
tubes. Samples were processed within 2 hours of collection by double spinning of 
blood first at 10 minutes at 1000 g then plasma 10 minutes at 2000 g. Plasma was 
stored in 1 ml aliquots at – 80 °C. Up to 5 ml of plasma per case was available for 
this study (range 1-5 ml, median 5 ml). The entire volume of plasma was used for 
cfDNA extraction. cfDNA was extracted using the QIAamp Circulating Nucleic 
Acid kit (Qiagen) and eluted into 50 µ l DNA Suspension Buffer (Sigma). Every 
cfDNA sample was analyzed on the Bioanalyzer High Sensitivity (Agilent) and 
quantified by interpolation of the mononucleosomal peak height on a calibration 
curve prepared from a pure cfDNA sample that was quantified previously.
cfDNA library preparation. Forty uL of cfDNA from each plasma sample, which is 
present as fragments of mononucleosomal and polynucleosomal length, was used 
as input into Library Prep using the Natera Library Prep kit; in two samples with 
extremely high cfDNA amounts input was restricted to ∼ 50,000 genome equiva-
lents (165 ng). cfDNA was end repaired and A-tailed. Natera custom adapters were 
ligated. The libraries were amplified for 15 cycles to plateau and then purified using 
Ampure beads following the manufacturer’s protocol. The purified libraries were 
run on the LabChip. Successful libraries had a single peak at ∼ 250 bp.
SNV assay design & optimization. Natera’s standard assay design pipeline was 
used to generate forward and reverse PCR primers for somatic SNVs detected in 
tumor samples. For every pair of primers, the probability of forming primer-dimer 
was calculated and assays were combined into pools such that any primer combina-
tion in a pool is not predicted to form primer-dimers. For each patient, assays were 
prioritized such that, 1) assays covering driver SNVs had highest priority, and 2) 
there was uniform sampling of the phylogenetic tree. For the baseline cohort, 
10 balanced pools were created, each containing the on average 18 assays for 
10 patients’ SNVs. For the longitudinal cohort, up to 10 extra assays were generated 
for adenocarcinoma samples. For patient CRUK0063 post mortem analysis, new 
assays were designed based on M-seq of metastatic biopsy retrieved at day 467 
and of metastatic lesions harvested post mortem. A total of 103 new assays were 
designed compared to 19 based on the primary tumor alone.
SNV assays were ordered from IDT (Coralville, IA). Each pool was optimized 
by running the multiplex PCR and sequencing protocol using one plasma cfDNA 
library from a healthy subject. For optimization, PCR parameters (primer concen-
tration and annealing temperature) that yielded the best percentage of on-target 
reads, depth-of-read uniformity (measured as the ratio of the 80th percentile/20th 
percentile), and number of drop-out assays (defined as assays with < 1,000 reads) 
were determined by sequencing. The PCR conditions that yield the best percentage 
of on-target reads, depth-of-read uniformity, and the lowest number of drop-outs 
were determined. For all pools, the optimal conditions were 10 nM primers and 
60 °C or 62.5 °C annealing temperature. Primer pairs contributing to dimer for-
mation were removed from each final pool.
Analytical validation. Synthetic spikes representing twenty SNVs randomly 
selected from Pool 1 were designed and synthesized (IDT, Coralville, IA) as 160 bp 
oligos with the respective SNV placed in the middle (position 80). These synthetic 
spikes were mixed at equimolar ratios and used to prepare a library. This library 
was titrated into a library prepared from mono-nucleosomal DNA (10,000 copies) 
from a normal cell line (AG16778 from Coriell, Camden, NJ). The library of 20 
synthetic spikes was titrated into the mononucleosomal DNA library at 2.5%, 0.5%, 
0.25%, 0.1%, 0.05% and 0% (each in triplicate), and 0.01%, 0.005% and 0.001% 
(each in quadruplicate. Because preparing spiked samples at such low levels is 
either subject to sampling noise (0.01% spikes into 10,000 genomic copies back-
ground is equivalent to one mutant copy), or is not possible (at levels less than 
0.01%), samples were mixed as libraries. Following library mixing and sequencing, 
data was analyzed to detect all the targets in Pool 1 using the same parameters as 
used for the patient samples.
The measured VAF of each spike for the samples with 2.5% nominal input was 
used to calculate an input correction factor (measured VAF/2.5%). This correc-
tion factor was applied to the other inputs of the corresponding spike titration 
series. The measured VAF differed from the nominal input most likely because the 
mononucleosomal fragmentation pattern is not entirely random. Because of this, 
the actual input levels differ from the nominal input levels. Therefore, analytical 
sensitivity and specificity were measured based on corrected input intervals (see 
Extended Data Fig. 1a).
Plasma SNV mPCR-NGS workflow. The library material from each plasma sam-
ple was used as input into multiplex PCR using the relevant assay pool and an 
optimized plasma mPCR protocol. Optimal mPCR conditions were as described10. 
Each PCR assay pool was used to amplify the SNV targets from the 10 corre-
sponding samples and 20 negative control samples (plasma libraries prepared from 
healthy subjects; BioMed IRB #601-01 and E&I West Coast Board IRB00007807, 
Study #13090-01A and 13090-04A). The mPCR products were barcoded in a sep-
arate PCR step. Each amplicon pool was sequenced on one Illumina HiSeq 2500 
Rapid Run with 50 cycles paired-end reads using the Illumina Paired End v1 kit 
with an average target DOR of ∼ 40,000 per assay.
Bioinformatics Pipeline. All the paired-end reads were merged using Pear26. 
Merged reads were mapped to the hg19 reference genome with Novoalign v2.3.4 
(http://www.novocraft.com/) and sorted and indexed using SAMtools27. Bases 
that did not match in forward and reverse reads or that have Phred quality score 
< 20 were filtered out to minimize sequencing errors in subsequent steps. Merged 
reads with mapping quality > 30 and at most one mismatch under the sequence 
of primers were marked as on-target. Targets with < 1000 reads were considered 
failed and were filtered from further analyses. Quality control was performed using 
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an in-house program checking for a wide list of statistics per sample that included 
total numbers of reads, mapped reads, on-target reads, number of failed targets, 
and average error rate.
Plasma SNV calling algorithm. For each target SNV a position-specific error-
model was built (see Supplementary Methods). Samples with high plasma VAF 
(> 20%) among the putative negatives were considered to have possible germline 
mutations and were excluded from the error model. A confidence score was calcu-
lated for each target SNV based on the error model and a positive plasma SNV call 
was made if the confidence score passed a threshold of 95% for transitions and 98% 
for transversions (see Supplementary Methods). There was no difference in depth 
of read between called and not called SNVs (Extended Data Fig 1c).
Because the post mortem analysis of CRUK0063 involved a larger number of 
target SNVs per time point being analyzed (103 vs. 19 targets in previous sam-
ples) updated calling thresholds were applied to control for false positives. The 
new updated thresholds were chosen such that the average number of false pos-
itives in the 30 negative samples in the run becomes ∼ 1 per sample. All multi-
plex PCR-NGS ctDNA SNV assays with confidence score data are available in 
Supplementary Table 5 (Baseline, pre-operative cohort assays), Supplementary 
Table 6 (Longitudinal Assays), and Supplementary Table 7 (Extended Longitudinal 
Assays for CRUK0063).
Cross-platform validation using generic PCR-NGS panel section. Cross-
platform validation was performed in 28 patients with M-Seq confirmed SNV(s) 
within one or more hotspots targeted by a generic multiplex PCR-NGS panel 
(Extended Table 2a-b, Supplementary Table 8). 20 ng of isolated cfDNA was used 
for library preparation using the Oncomine™ Lung cfDNA Assay (ThermoFisher 
Scientific), according to the manufacturer’s instructions. Automated template 
preparation and chip loading was conducted on the Ion Chef™ instrument using the 
Ion 520™ & Ion 530™ Kit-Chef (ThermoFisher Scientific). Ultimately, samples were 
sequenced on Ion 530™ chips using the Ion S5™ System (ThermoFisher Scientific). 
Sequencing data was accessed on the Torrent suite v5.2.2. Reads were aligned 
against the human genome (hg19) using Alignment v4.0-r77189, and variants were 
called using the coverage Analysis v4.0-r77897 plugin. All 18 bespoke-panel ctDNA 
negative patients had no tumor SNVs detectable in plasma pre-operatively by the 
generic panel supporting biological specificity of the bespoke targeted approach, 7 
of 10 bespoke-panel ctDNA positive patients had tumor SNVs detected in plasma 
by the generic panel (Extended Table 2a-b). SNVs detected by hotspot panel not 
identified by M-Seq are displayed in Extended Table 2c.
Processing and phylogenetic analysis of relapse and primary tumor multire-
gion whole exome data. Biopsies from multiple regions from the primary tumor 
(n = 327), metastatic biopsies (n = 4) and matching blood germline samples 
(n = 100) were subjected to multi-region whole exome sequencing and analysis 
including estimation of copy number, purity and ploidy, and phylogenetic tree 
construction as described9. Briefly, phylogenetic analysis was performed based 
on CCF determined for SNVs and clustered across tumor regions using a mod-
ified version of Pyclone9 into clusters with similar CCF values, filtered and pro-
cessed as described9. Mutation clusters are assumed to represent tumor subclones, 
either current or ancestral, and are used as input for construction of phylogenetic 
relationship. Phylogenetic trees were primarily constructed using the published 
tool CITUP (0.1.0)28. However, in a small number of cases, including all relapse/
autopsy cases, manual tree construction was required and performed as described9. 
Complete detail of primary tumor tree construction can be found in Jamal-Hanjani 
et al. 20179. Relapse tree construction was performed as follow: CRUK0063: clus-
tering was performed twice, once across 5 primary tumor regions and once across 
5 primary, 1 relapse, and 6 autopsy regions. To ensure consistency, when deriving a 
phylogenetic tree based on all tumor regions, CCF clusters based on clustering only 
the primary tumor regions were maintained for mutations not involved in meta-
static relapse. A phylogenetic tree was constructed based on 17 mutation clusters. 
CRUK0035: Clustering primary tumor regions with the relapse region revealed one 
cluster private to the relapse, and one cluster shared with the relapse and all other 
regions. CRUK0044: Clustering primary tumor regions with the relapse region 
revealed a cluster private to the relapse, descended from a cluster private to region 
1 in the primary tumor. CRUK0041: Clustering primary tumor regions with the 
relapse region revealed cluster 4 as private to the relapse. This cluster must have 
evolved from cluster 3 only found in the relapse and in region 4. A private cluster 
6 in region 4 must have evolved from cluster 4. However, this conflicts with clusters 
2 and 5, found in the relapse and regions 1-3, but not region 4. This can be recon-
ciled by assuming a polyclonal relapse, seeded primarily from regions 1-3, but with 
some contribution from cluster 3, private to region 4. Cluster data is available in 
Supplementary Table 4 under “PyClonePhyloCluster”.
Statistical data analysis. Analysis was performed in the R statistical envi-
ronment version 3.2.3 and SPSS version 24. All statistical tests were two-sided 
unless expressly stated. Multivariate logistic regression used detection of ctDNA 
(the dependent variable) classified as detection of 2 or more patient-specific var-
iants in ctDNA and the covariates listed in Supplementary Table 1. All predictors 
were entered simultaneously into the regression. All continuous independent 
variables were found to be linearly related to the logit of the dependent variable 
(assessed via the Box-Tidwell procedure). The logistic regression model was sta-
tistically significant, X2(10) = 81.35, P < 0.001 and the Hosmer-Lemeshow P value 
was 0.9858 indicating that the model was not a poor fit. To determine the ability 
of PET TBR to predict whether or not tumor ctDNA was identified in plasma, 
PET TBR estimates were analyzed by ROC curve analysis against binary detection 
of ctDNA in plasma at baseline based on at least two variants detected, signifi-
cance test based on Wilcoxon rank sum test. For analysis involving longitudinally 
detected variants (Fig. 4, Extended Figure 5), only subclonal variants from pyclone 
clusters present in phylogenetic trees were displayed, this did not affect ctDNA 
detection status of any time-points. In non-relapse cases presented in Extended 
Data Fig 6 all detected subclonal SNVs were plotted. To determine the relation-
ship between tumor volume and ctDNA VAF, ctDNA assays against clonal SNVs 
were selected. For each patient, the mean ctDNA VAF of the clonal SNVs was 
determined as baseline for 38/46 patients with at least 2 SNVs detected in plasma. 
As detailed in Extended Fig. 4c, 8/46 patients were not included in the analysis: 
CRUK0036 had no pre-op CT scan available, CRUK0087 had a large cavity inside 
the primary cancer, RUK0099 had a collapsed lung making volume assessment 
inaccurate, CRUK0100, CRUK0077, CRUK0052 had a CT slice spacing of > 5 mm, 
and finally CRUK0088 and CRUK0091 had a total tumor volume < 3.5 cm3. Linear 
regression was performed on log-transformed mean VAF and tumor volume. The 
log transformation was justified as it symmetrized the residuals in the model. An 
independent analysis was performed where tumor volume was multiplied with 
tumor purity to estimate the cancer cell volume. The same log transformation and 
analysis was applied to data acquired from Newman et al.16, where ctDNA VAF 
was determined based on CAPP-seq analysis with matched tumor volume data 
available. To analyze clone size versus ctDNA VAF for subclonal SNVs, the mean 
CCF of the mutations within a subclonal mutation cluster was multiplied with 
tumor volume, and as a second independent analysis, with tumor purity.
Data availability. Sequence data has been deposited at the European Genome-
Phenoma Archive (EGA), which is hosted by the The European Bioinformatics 
Institute (EBI) and the Centre for Genomic Regulation (CRG), under accession 
numbers EGAS00001002247 (primary tumor data) and EGAS00001002415 
(metastatic tumor data). Further information about EGA can be found on https://
ega-archive.org, “The European Genome-phenome Archive of human data con-
sented for biomedical research”.
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Extended Data Figure 1 | Multiplex-PCR next-generation sequencing 
platform analytical validation. a) Analytical validation of the multiplex-
PCR NGS platform was performed by spiking synthetic single nucleotide 
variants into control cell-free DNA. Sensitivity and specificity of the 
platform at different spike concentrations was ascertained, 95% binomial 
confidence interval displayed as error bars. b) Specificity of ctDNA 
detection based on a 1 SNV and 2 SNV call threshold taking into account 
parallel testing of multiple SNVs. c) The median depth of read across a 
position did not vary depending on whether an SNV position was called 
or not called using the platform error-model. Wilcoxon Test, P = 0.786, 
median depth of read at uncalled positions = 45,777 (n = 3,745), range:  
0 to 146774, median depth of read at called positions = 45,478, 
range = 1,354 to 152,974 (n = 1,124). Whiskers represent 1.5 times the 
interquartile range, 2-sided test.
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Extended Data Figure 2 | Study construction and assay-panel design.  
a) The pre-operative study phase cohort consisted of 100 TRACERx 
patients present in the first 100 patient TRACERx cohort in April 2016. 
Pre-operative plasma samples were profiled in 96 patients for reasons 
listed. bi and ii) Contents of patient-specific assay-panels designed in the  
pre-operative study phase. c) The longitudinal study phase cohort 
consisted of patients with confirmed NSCLC relapse and patients without 
relapse. d) Contents of patient-specific assay-panels designed in the 
longitudinal phases of this study. e) Single nucleotide variant type targeted.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
A
C
C
E
L
E
R
A
T
E
D
 A
R
T
IC
L
E
 P
R
E
V
IE
W
ARTICLE RESEARCH
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
PET TBR ROC−curve
1−specificity
S
e
n
s
it
iv
it
y
AUC = 0.84, P = 1.4e−08
d
c
TP53 driver
TotalNoYes
No
Yes
Total
2324 47
74 11
3028 58
ctDNA
detected
Fishers Exact Test P=0.508
LUAD
KRAS driver
TotalNoYes
Total
2720 47
83 11
3523 58
ctDNA
detected
EGFR driver
Total
Total
3611 47
101 11
4612 58
NoYes
ctDNA
detected No
Yes
No
Yes
Fishers Exact Test P=0.499
Fishers Exact Test P=0.429
Histological subtype
TNM Stage
TotalI II III
LUAD
No
Yes
LUSC
No
Yes
Other
No
Yes
34 7 6 47
5 2 4 11
1 0 0 1
16 12 2 30
2 0 0 2
1 2 2 5
ctDNA
detected
ctDNA
detected
ctDNA
detected
a
0
50
100
LUSC Negative 
  LUAD
Positive
LUAD
%
N
ec
ro
si
s 
P<0.001
P=0.047
P=0.050
b
Predictors of ctDNA     detection    by multiplex-PCR NGS in early stage NSCLC
Univariable analysis Multivariable analysis
 OR (95% CI)                  P-value
Clinicopathological variables
Non-adenocarcinoma histology
%Ki67+ cells (10% increase)
Lympho-vascular invasion
Necrosis (10% increase)
Male gender
Age (years)
Technical variables
cfDNA input (ng)
Ubiquitous SNVs in assay-panel
<0.001
<0.001
0.028
<0.001
0.172
0.115
0.028
0.341
49.85 (12.93 -192.19) 
1.72  (1.40 - 2.12)
2.53  (1.10 - 5.80)
2.16  (1.58 - 2.97)
1.80  (0.78 - 4.16)
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e
Extended Data Figure 3 | Clinicopathological predictors of ctDNA 
detection. a) 96 patients in pre-operative cohort stratified by pathological 
TNM stage. b) LUSCs and ctDNA positive LUADs are significantly more 
necrotic that ctDNA negative LUADs. Significant differences in necrosis 
between groups: LUSCs (median necrosis 40%) (n = 31), ctDNA positive 
LUADs (median necrosis 15%) (n = 11) and ctDNA negative LUADs 
(median necrosis 2%) (n = 47), Kruskal-Wallis test, P < 0.001, 2-sided 
pairwise comparisons were performed using Dunn’s procedure with 
Bonferroni correction. c) Univariate (left) and multivariate analyses (right) 
were performed, by logistic regression to determine significant predictors 
of ctDNA detection in early-stage NSCLC. ctDNA detection was defined 
as detection of two or more SNVs in pre-operative plasma samples. Details 
regarding multivariable analysis methodology are in methods. d) Receiver 
operating characteristic curve (ROC) analysis of pre-operative PET scan 
FDG-avidity (normalized as tumor background ratio (TBR), see methods), 
as a predictor of ctDNA detection (92/96 PET scans were available for 
central review). Median PET TBR of detected tumors = 9.01, n = 45. 
Median PET TBR of undetected tumors = 3.64, n = 47. P-value based on 
Wilcoxon Rank Sum Test. e) LUAD subtype analyses based on ctDNA 
detection and the presence of an EGFR, KRAS or TP53 driver mutation.
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Extended Data Figure 4 | Predictors of plasma variant allele frequency. 
a) Plasma variant allele frequencies of SNVs detected in plasma in 46 
patients who were ctDNA positive (two or more SNVs detected). Clonal 
(blue) and subclonal (red) variant allele frequencies indicated, mean 
shown as horizontal line. Driver variants shown as triangles. b) Mean 
clonal VAF correlated with maximum tumor size measured in post-
surgical specimen (pathological size, n = 46) grey vertical bars represent 
range of clonal variant allele frequency. Shaded red background indicates 
95% confidence interval. c) Filtering steps taken to define a group of 
ctDNA positive patients with volumetric data considered adequate to 
model tumor volume and plasma variant allele frequency. d) Scatter 
plot showing mean clonal VAF relative to tumor volume for TRACERx 
(blue dots and fitted blue line, n = 38) and VAF relative to volume for 
previously published data based on CAPP-seq analysis of ctDNA (orange 
dots and orange fitted line, n = 9). Orange shaded background indicates 
95% confidence interval based on CAPP-seq data. e) Mean clonal VAF 
correlated with tumor volume × tumor purity (cancer cell volume), n = 38. 
Shaded red background indicates 95% confidence interval. f) Association 
between number of cancer cells and VAF of clonal SNVs in plasma based 
on linear modelling of Extended Data Fig 4f. g) Detected subclonal SNVs 
were mapped back to M-Seq derived tumor phylogenetic trees (process 
illustrated in graphic). Detected private subclones (subclones identified 
within only a single tumor region) are coloured red. Shared subclones 
(subclones detected in more than one tumor regions) are light blue. 
Subclonal nodes were sized based on the maximum recorded cancer cell 
fraction (CCF). The top row of phylogenetic trees represent subclonal 
nodes targeted by primers within that patient’s assay panel, the bottom 
row represent subclonal nodes detected in ctDNA, within this row grey 
subclonal nodes represent subclones not detected in ctDNA.
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Extended Data Figure 5 | Longitudinal ctDNA profiling, remaining 
relapse cases. a) Kaplan-Meier curve demonstrate relapse free survival for 
patients in whom ctDNA was detected versus patients in whom ctDNA 
was not detected. b-h) Longitudinal cell-free DNA profiling. Circulating 
tumor DNA (ctDNA) detection in plasma was defined as the detection 
of two tumor-specific SNVs. Relapse was based on imaging-confirmed 
NSCLC relapse, imaging performed as clinically indicated. Detected clonal 
(circles, light blue) and subclonal (triangles, colors indicates different 
subclones) SNVs from each patient-specific assay-panel are plotted on 
graphs colored by M-Seq derived tumor phylogenetic nodes. Mean  
clonal (blue) and mean subclonal (red) VAF are indicated on graphs.  
Pre-operative and relapse M-Seq derived phylogenetic trees represented 
by ctDNA are illustrated above each graph in cases where subclonal SNVs 
were detected.
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Extended Data Figure 6 | Longitudinal ctDNA profiling, non-relapse cases. a-j) Detected clonal (circles, light blue) and subclonal (red triangles) SNVs 
from each patient-specific assay-panel are plotted on graphs. Mean clonal (blue) and mean subclonal (red) VAF are indicated on graphs.
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Extended Data Figure 7 | Heatmaps illustrating detection of SNVs in 
bespoke panel at each sampled time point. a, c-f) Bespoke assay panels 
for CRUK0063, CRUK0035, CRUK0044, CRUK0041 and CRUK0013. 
Colors indicate originating subclonal cluster based on the phylogenetic 
trees above the heatmap. Light blue indicates clonal mutation cluster. 
Full panel with cluster color shown below each heatmap. Filled squares 
indicates detection of a given variant in plasma ctDNA. Y-axis shows 
day of sampling, y-axis labels appended with [R] indicates day of clinical 
relapse. b) Re-examination of primary tumor regions from CRUK0063 
with lowered threshold to potentially identify SNVs private to the 
sequenced relapse biopsy. 16/88 variants were found at very low VAF in 
region 3, indicating this region from the primary likely gave rise to the 
metastasis.
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Extended Data Figure 8 | Heatmap illustrating detection of SNVs in 
bespoke panel based on M-seq of metastatic tumor regions for patient 
CRUK0063 for all sampled time points. Colors indicate originating 
subclonal cluster based on the phylogenetic trees above the heatmap. Light 
blue indicates clonal mutation cluster. Full panel with cluster color shown 
below each heatmap. Filled squares indicates detection of a given variant 
in plasma ctDNA. Y-axis shows day of sampling.
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Extended Data Table 1 | Patient characteristics
a) table of clinical characteristics describing the 96 patient pre-operative cohort and b) demonstrating distribution of stage and whether the patient received adjuvant chemotherapy, c) demonstrating 
the time-points at which pre-operative plasma was acquired for patients within the cohort, d) table of clinical characteristics describing 24 patient longitudinal cohort and e) demonstrating distribution 
of stage in the longitudinal cohort and whether the patient received adjuvant chemotherapy.
Total
Age <60 19
≥60 77
Sex Male 60
Female 36
ECOG PS 0 49
1 47
Histology Adenocarcinoma 58
Squamous cell 
carcinoma
31
Carcinosarcoma 2
Large cell carcinoma 1
Adenosquamous 
carcinoma
Large cell 
neuroendocrine 1
TNM stage Ia 24
Ib 35
IIa 12
IIb 11
IIIa 13
IIIb 1
Lymph node 
metastasis
Yes 24
No 72
Pleural 
involvement
Yes 27
No 69
Vascular 
invasion
Yes 41
No 55
Resection
margin
R0 91
R1 5
Smoking 
status
Never smoked 11
Recent ex-smoker 30
Ex-smoker 48
Ethnicity
Clinical characteristics 
96 patient  pre-operative cohort
Characteristic
No adjuvant therapy Adjuvant therapy
TNM Stage Ia 24 0
Ib 31 4
IIa 3 9
IIb 4 7
IIIa 6 7
IIIb 0 1
a
b
Clinical characteristics 
24 patient  longitudinal sub-cohort
Total
Age <60 5
≥60 19
Sex Male 16
Female 8
ECOG PS 0 12
1 12
Histology Adenocarcinoma 16
Squamous cell 
carcinoma
8
TNM stage Ia 3
Ib 7
IIa 3
IIb 7
IIIa 3
IIIb 1
Lymph node 
metastasis
Yes
No
Pleural 
involvement
Yes 7
No 17
Vascular 
invasion
Yes 12
No 12
Resection
margin
R0 23
R1 1
Smoking 
status
Never smoked
1
Recent ex-smoker 5
Ex-smoker 16
21
2
Caribbean 1
Characteristic
No adjuvant therapy Adjuvant therapy
TNM Stage Ia
Ib
IIa
IIb
IIIa
IIIb
d
e
White-other
White BritishEthnicity
Current smoker 2
White British 85
White-other 4
White-Irish 4
Caribbean 3
Current smoker 7
1
2
5
3
1
03
6
0
2
1
0
9
15
carcinoma
3
Number Details
Within 24 hours 91
2
c
Days pre-surgery
24-72 hours
8 days
31 days
2
1
CRUK0073, 0096
CRUK0089
CRUK0051, 0003
Details regarding timing of pre-operative blood sample
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Extended Data Table 2 | Cross platform validation using a generic approach to ctDNA profiling
a) 7/10 (70%) of bespoke-panel ctDNA positive patients had tumor SNVs detectable in plasma preoperatively by a generic hotspot PCR-NGS lung panel (Lung Oncomine, Thermoisher). The three 
bespoke-panel ctDNA positive patients undetected by the generic panel had mean clonal plasma variant allele frequencies lower than the 0.1% plasma variant allele frequency (VAF) limit of detection 
reported for the generic panel (shaded yellow). b) Based on CT volumetric assessment of each patient’s primary tumor we predicted plasma VAF corresponding to a tumor of that size (see Fig. 3 and 
Methods for details of approach). This allowed us to infer platform sensitivities for each patient within the bespoke-panel non-detected cohort. Five LUADs (shaded green, CRUK0037, CRUK0051, 
CRUK0004, CRUK0039 and CRUK0025) had tumor volumes approximating to a plasma VAF of more than 0.1%. This suggested that these tumors resided within the top platform sensitivity bracket of 
both the generic and bespoke-panel ctDNA platforms. No ctDNA was detected by either platform in these cases, suggesting biological speciicity of the bespoke-panel. c) Hotspot SNVs not identiied 
in tumor tissue through exome sequencing were identiied in plasma of 9 of 28 patients by the generic panel. This suggested non-tumor origin of cell-free DNA, platform non-speciicity or an evolving 
minor subclone or second primary.
Targeted 
panel 
>99% sensivity at 0.1% VAF and above
84% sensivity at 0.05% to 0.1% 
VAF
46 % sensivity 0.01% to 0.05% VAF
4.2% sensivity <0.01%
Generic 
panel 90% sensivity at 0.1% VAF and above
ND - non detected
DOR - depth of read
Combined exome VAF (unfiltered) - Variant allele frequency across all tumor regions analysed (without call filters).
Platform sensitivities predicted based on tumor volume
and analytical validation data in Extended Data 1
Oncomine lung panel sensitivity data reported at 
https://www.thermosher.com/order/catalog/product/A31149
Multiplex-PCR NGS
Case Volume cm3 Plasma VAF (mean clonal) ctDNA posive Histology Hotspot SNVs tumor Hotspot SNVs detected
CRUK0029 38.51 2.10 Yes LUAD 1 1
CRUK0009 69.01 1.71 Yes LUAD 1 1
CRUK0062 58.48 1.41 Yes LUSC 1 1
CRUK0081 16.41 0.21 Yes LUSC 1 1
CRUK0089 17.39 0.16 Yes LUSC 1 1
CRUK0022 17.20 0.08 Yes LUAD 1 0
CRUK0067 6.64 0.07 Yes LUSC 1 0
CRUK0052 43.69 0.06 Yes LUAD 2 1
CRUK0064 9.24 0.05 Yes LUSC 1 0
CRUK0034 10.59 0.01 Yes LUAD 1 1
Table 2 b - Bespoke panel non-detected NSCLCs - cross platform validation
Case Volume cm3 Predicted plasma VAF ctDNA posive Histology Hotspot SNVs tumor Hotspot SNVs detected
CRUK0037 197.42 2.89 (0.93 - 8.97) No LUAD 1 0
CRUK0051 27.28 0.30 (0.19 to 0.46) No LUAD 1 0
CRUK0004 23.30 0.25 (0.16 to 0.38) No LUAD 1 0
CRUK0039 21.68 0.23 (0.15 to 0.35) No LUAD 2 0
CRUK0025 19.06 0.20 (0.13 to 0.30) No LUAD 2 0
CRUK0014 8.58 0.08 (0.04 to 0.15) No LUAD 1 0
CRUK0026 7.45 0.07 (0.04 to 0.13) No LUAD 1 0
CRUK0057 5.95 0.05 (0.02 to 0.11) No LUAD 1 0
CRUK0018 4.65 0.04 (0.02 to 0.09) No LUAD 1 0
CRUK0027 4.61 0.04 (0.02 to 0.09) No LUAD 1 0
CRUK0007 4.18 0.04 (0.01 to 0.08) No LUAD 1 0
CRUK0049 3.61 0.03 (0.01 to 0.08) No LUAD 1 0
CRUK0035 3.31 0.03 (0.01 to 0.07) No LUAD 1 0
CRUK0058 2.76 0.02 (0.01 to 0.06) No LUAD 1 0
CRUK0021 2.70 0.02 (0.01 to 0.06) No LUAD 2 0
CRUK0048 2.16 0.02 (0.01 to 0.05) No LUAD 2 0
CRUK0093 0.73 0.004 (0 to 0.03) No LUSC 2 0
CRUK0030 0.21 0.001 (0 to 0.01) No LUAD 2 0
(unltered) (unltered)
Case Gene Location Position Ref Variant AA change Plasma VAF DOR ctDNA positive Combined exome VAF Germline VAF 
CRUK0052 PIK3CA chr3 178936091 G A p.E545K 0.81 60360 Yes ND ND
CRUK0052 PIK3CA chr3 178952085 A G p.H1047R 0.12 52325 Yes 0.075 ND
CRUK0062 PIK3CA chr3 178936091 G A p.E545K 0.97 89616 Yes 0.016 ND
CRUK0062 PIK3CA chr3 178952085 A G p.H1047R 0.05 79205 Yes 0.005 ND
CRUK0062 TP53 chr17 7577556 C A p.C242F 0.05 93383 Yes ND ND
CRUK0089 TP53 chr17 7577121 G A p.R273C 0.06 59849 Yes 0.168 ND
CRUK0004 PIK3CA chr3 178936091 G A p.E545K 0.59 73941 No 0.081 ND
CRUK0018 PIK3CA chr3 178936091 G A p.E545K 4.44 99159 No ND ND
CRUK0018 PIK3CA chr3 178952085 A G p.H1047R 0.81 77806 No 0.044 ND
CRUK0021 PIK3CA chr3 178952085 A G p.H1047R 0.11 50107 No ND ND
CRUK0027 PIK3CA chr3 178952085 A G p.H1047R 0.11 65449 No ND ND
CRUK0037 PIK3CA chr3 178952085 A G p.H1047R 0.09 51071 No ND ND
CRUK0058 KRAS chr12 25398284 C A p.G12V 3.44 63090 No 0.124 ND
Table 2 c - Variants detected by generic PCR-NGS hotspot panel not detected in M-Seq analysis of tumor
Bespoke-panel
Bespoke-panel
Generic-panel
Generic-panel
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